It’s traditional to end the year with a look back at what you hoped to accomplish and an assessment of what you did. By that standard 2016 has been a pretty good year for us at CIRM.
Yesterday our governing Board approved funding for two new clinical trials, one to help kidney transplant patients, the second to help people battling a disease that destroys vision. By itself that is a no small achievement. Anytime you can support potentially transformative research you are helping advance the field. But getting these two clinical trials over the start line means that CIRM has also met one of its big goals for the year; funding ten new clinical trials.
If you had asked us back in the summer, when we had funded only two clinical trials in 2016, we would have said that the chances of us reaching ten trials by the end of the year were about as good as a real estate developer winning the White House. And yet……..
Helping kidney transplant recipients
The Board awarded $6.65 million to researchers at Stanford University who are using a deceptively simple approach to help people who get a kidney transplant. Currently people who get a transplant have to take anti-rejection medications for the rest of their life to prevent their body rejecting the new organ. These powerful immunosuppressive medications are essential but also come with a cost; they increase the risk of cancer, infection and heart disease.
The Stanford team will see if it can help transplant patients bypass the need for those drugs by injecting blood stem cells and T cells (which play an important role in the immune system) from the kidney donor into the kidney recipient. The hope is by using cells from the donor, you can help the recipient’s body more readily adjust to the new organ and reduce the likelihood the body’s immune system will attack it.
This would be no small feat. Every year around 17,000 kidney transplants take place in the US, and many people who get a donor kidney experience fevers, infections and other side effects as a result of taking the anti-rejection medications. This clinical trial is a potentially transformative approach that could help protect the integrity of the transplanted organ, and improve the quality of life for the kidney recipient.
The second trial approved for funding is one we are already very familiar with; Dr. Henry Klassen and jCyte’s work in treating retinitis pigmentosa (RP). This is a devastating disease that typically strikes before age 30 and slowly destroys a person’s vision. We’ve blogged about it here and here.
Dr. Klassen, a researcher at UC Irvine, has developed a method of injecting what are called retinal progenitor cells into the back of the eye. The hope is that these cells will repair and replace the cells damaged by RP. In a CIRM-funded Phase 1 clinical trial the method proved safe with no serious side effects, and some of the patients also reported improvements in their vision. This raised hopes that a Phase 2 clinical trial using a larger number of cells in a larger number of patients could really see if this therapy is as promising as we hope. The Board approved almost $8.3 million to support that work.
Seeing is believing
How promising? Well, I recently talked to Rosie Barrero, who took part in the first phase clinical trial. She told me that she was surprised how quickly she started to notice improvements in her vision:
“There’s more definition, more colors. I am seeing colors I haven’t seen in years. We have different cups in our house but I couldn’t really make out the different colors. One morning I woke up and realized ‘Oh my gosh, one of them is purple and one blue’. I was by myself, in tears, and it felt amazing, unbelievable.”
Amazing was a phrase that came up a lot yesterday when we introduced four people to our Board. Each of the four had taken part in a stem cell clinical trial that changed their lives, even saved their lives. It was a very emotional scene as they got a chance to thank the group that made those trials, those treatments possible.
We’ll have more on that in a future blog.
8 thoughts on “California’s stem cell agency rounds up the year with two more big hits”
Kevin, is there any way to get on a national list for lung regeneration, whenever they become available? Thanks! Lynn
Dear Lynn, thanks for the comment. There is no national list for lung regeneration I’m afraid. There are individual clinical trials that you can sign up for, although even that’s no guarantee you will be a part of one. However, if you send me your email (I’m at email@example.com) I can add you to our Stem Cell Champions group and also our lung disease group to ensure you get updates on this research.
You guy’s wotk is a true testament of mankind. Thank you for all that you’re doing.
You guy’s work is a true testament of mankind. Thank you for all that you’re doing.
Are there any islet cells transplantation hospitals or research centers for Diabetics Type 1 in or near Los Angeles, CA?
Dear Susana, I know that City of Hope in Duarte – near Los Angeles – has an islet cell transplant program. Here’s a link to information about that:
I hope that help.
Does stem cell therapy for retinitis pigmentosa continue to improve over time greater than 1 year, or has the improvement leveled off after some months?
Dear Saleem, for some of the patients treated in the first group the improvements continued over the course of a year. Rosie Barrero described it as like peeling away layers of an onion; every so often another layer would peel off and her vision would be just a little bit sharper. Other patients didn’t experience those same improvements so we are going to be very interested to see how this second group – currently being treated – does and if any improvements continue over time.